The FDA is still without a permanent leader as the clock ticks down. Dr. Janet Woodcock is serving as the acting leader of the agency, but legally she can only stay on as acting head through November 15, unless a permanent commissioner is nominated.
The clock is ticking down on the time President Joe Biden has to appoint a permanent head to the US Food and Drug Administration -- an agency critical to fighting the coronavirus pandemic -- with no outward signs he has a candidate in mind.
Dr. Janet Woodcock is serving as the acting leader of the agency, but legally she can stay on as acting head only through November 15, unless a permanent commissioner is nominated.Last month, the White House would not predict what the timeline was for nominating a permanent head. "The role of the FDA commissioner is critically important, as you all know, especially during the Covid-19 pandemic," White House deputy press secretary Karine Jean-Pierre told reporters Tuesday.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Johnson & Johnson Asks FDA to Authorize Covid-19 BoosterJohnson & Johnson has asked U.S. health regulators to authorize a booster dose for its Covid-19 vaccine, citing studies showing it improved protection among adults who previously received a single shot
Lire la suite »
Johnson & Johnson Requests FDA Approval for Vaccine Booster DosesJohnson & Johnson asked the FDA on Tuesday to authorize an extra dose of its COVID-19 vaccine as a booster shot.
Lire la suite »
AstraZeneca asks FDA to authorize Covid antibody treatment to prevent illnessIf authorized, it would be the first long-acting drug for people with compromised immune systems who don't get sufficient protection from vaccination.
Lire la suite »
AstraZeneca asks FDA to approve COVID antibody drug for those with weakened immune systemsLate-stage human trials showed that AstraZeneca's antibody drug reduced the risk of developing symptomatic COVID-19 by 77 percent.
Lire la suite »
US child Covid-19 deaths are an 'embarrassment,' FDA vaccines head saysAfter weeks of a troubling Covid-19 surge across the US, infection rates are finally on the decline — but experts say there's still work to be done before the tide can be turned, especially when cases remain exceptionally high among children.
Lire la suite »